CTCF, a novel fusion partner of ETO2 in a post-transplant relapsed acute myeloid leukemia patient

Abstract

<jats:title>Abstract</jats:title> <jats:p>Background ETO2 is a nuclear co-repressor, which plays a critical role in the regulation of the cell cycle, self-renewal capacity, and differentiation of hematopoietic progenitor cells. Methods We identified novel fusion transcripts involving <jats:italic>ETO2</jats:italic> and <jats:italic>CTCF</jats:italic> by RNA-seq in a post-transplant relapsed case. Results The <jats:italic>CTCF-ETO2</jats:italic> and <jats:italic>ETO2-CTCF</jats:italic> chimeric genes were validated by RT-PCR and Sanger sequencing. In addition, both transcripts apparently promoted cell proliferation which is beneficial to tumorigenesis. Conclusion The novel fusions may have prognostic value and pathogenic mechanisms in acute myeloid leukemia.</jats:p>